MENU
+Compare
IMUC
Stock ticker: OTC
AS OF
Nov 18 closing price
Price
$0.18
Change
-$0.00 (-0.00%)
Capitalization
22.64M

IMUC stock forecast, quote, news & analysis

EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve the lives of patients suffering from debilitating and sometimes deadly diseases... Show more

Industry: #Biotechnology
IMUC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for IMUC with price predictions
Nov 18, 2025

IMUC's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for IMUC moved out of overbought territory on October 22, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 instances where the indicator moved out of the overbought zone. In of the 13 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on November 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IMUC as a result. In of 140 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IMUC just turned positive on November 18, 2025. Looking at past instances where IMUC's MACD turned positive, the stock continued to rise in of 69 cases over the following month. The odds of a continued upward trend are .

IMUC moved above its 50-day moving average on November 17, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IMUC crossed bullishly above the 50-day moving average on October 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +13 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUC advanced for three days, in of 94 cases, the price rose further within the following month. The odds of a continued upward trend are .

IMUC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 124 cases where IMUC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.355) is normal, around the industry mean (23.122). P/E Ratio (0.019) is within average values for comparable stocks, (61.014). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (332.704).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMUC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.15B. The market cap for tickers in the group ranges from 58 to 110.5B. VRTX holds the highest valuation in this group at 110.5B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 65%. MRSN experienced the highest price growth at 210%, while KRRO experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 53%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was 443%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 57
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
IMUC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of immune based therapies for the treatment of brain and other cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
136 Summit Avenue
Phone
+1 201 351-0605
Employees
4
Web
https://www.eompharma.com